Form 4: CARGO Therapeutics Director Kapil Dhingra Granted 25,000 Stock Options

CARGO Therapeutics, Inc. Director Kapil Dhingra was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.

Summary

• Kapil Dhingra, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options.
• The stock options have an exercise price of $4.35 per share.
• The grant date for these options was June 18, 2025.
• The options will vest 100% on the earlier of the one-year anniversary of June 18, 2025, or the next Annual Meeting following June 18, 2025, contingent on Mr. Dhingra's continued service to the Issuer.
• The options are set to expire on June 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of aligning management interests with shareholders and is a standard compensation practice, indicating stability in governance. It is not a major operational or financial announcement, hence a moderately positive score.

Positives

• The grant of stock options to Director Kapil Dhingra aligns his financial interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from a key board member, contributing to governance stability.

Future Outlook

This Form 4 filing details an equity grant to a director, which is a standard compensation practice and does not provide specific forward-looking statements regarding the company's operational or financial performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, aiming to align executive and board member incentives with long-term shareholder value creation. This type of equity compensation is a standard component of director remuneration packages across publicly traded companies.

Comparison to Industry Standards

• The grant of 25,000 stock options to a director is within the typical range for equity compensation for board members in the biotechnology sector, comparable to practices seen at companies like BioNTech SE or Moderna, Inc., where equity grants are used to attract and retain top talent and align interests with company performance.

Related Party Transactions

• The grant of 25,000 stock options to Kapil Dhingra, a Director of CARGO Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting all employees, this type of equity compensation for leadership can signal a commitment to attracting and retaining high-caliber talent at the board level.

Next Steps

• The stock options are scheduled to vest 100% on the earlier of June 18, 2026 (one-year anniversary of grant) or the date of the next Annual Meeting following June 18, 2025, subject to continued service.

Key Dates

Keywords

CARGO Therapeutics, CRGX, stock options, insider transaction, Form 4, Kapil Dhingra, director compensation, equity grant